Cefixime Limitations and Alternatives

Primary Reason: Removal from Gonorrhea Treatment Guidelines

The CDC no longer recommends routine use of cefixime as a first-line regimen for gonorrhea treatment in the United States due to rising minimum inhibitory concentrations (MICs) among Neisseria gonorrhoeae isolates 1, 2, 3, 4.
Between 2006 and 2011, isolates with elevated cefixime MICs increased from 0.2% to 1.4% nationally, with the West region showing an increase from 0.2% to 3.2% 2.
Among men who have sex with men (MSM), the percentage of isolates with elevated cefixime MICs increased from 0.2% in 2006 to 3.8% in 2011 2, 3.
This pattern mirrors the emergence of fluoroquinolone resistance in the 1990s, which also began in the West and among MSM before spreading nationwide 1, 2.

A 400-mg oral dose of cefixime does not provide bactericidal levels as high or as sustained as an intramuscular 250-mg dose of ceftriaxone 1, 2, 3, 4.
Cefixime demonstrates limited efficacy for treatment of pharyngeal gonorrhea, a critical limitation given that pharyngeal infections serve as reservoirs for resistant strains 1, 2, 3, 4.

Continued use of cefixime might hasten the development of resistance to ceftriaxone, which remains the last antimicrobial known to be highly effective in a single dose for gonorrhea treatment at all anatomic sites 1, 2, 3, 4.
Maintaining effectiveness of ceftriaxone for as long as possible is critical, making preservation of this agent a public health priority 1, 2, 3, 4.

For respiratory infections, cefixime offers no clear advantage over cefdinir, cefpodoxime, or amoxicillin-clavulanate, which are more established options 5, 6.
In pneumonia treatment, cefotaxime and ceftriaxone are preferred third-generation cephalosporins with better-established efficacy 7.

WHO's 2024 essential medicines recommendations do not include cefixime for any infection category, instead prioritizing cefotaxime, ceftriaxone, and other agents 8.
For intra-abdominal infections, the WHO recommends cefotaxime or ceftriaxone with metronidazole, not cefixime 8.
Cefepime remains acceptable for febrile neutropenia despite controversy, but cefixime is not mentioned as an alternative 9.

Never use cefixime for gonorrhea treatment given current CDC recommendations against its routine use 1, 2, 3, 4.
Do not use cefixime for pharyngeal infections when gonorrhea is a consideration, given its poor efficacy at this site 1, 2.